查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1460757

對比媒體市場- 全球產業規模、佔有率、趨勢、機會和預測，按類型、按程序（X光/電腦斷層掃描、磁振造影和超音波）、按適應症、按地區和競爭細分，2019-2029年

Contrast Media Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Procedure (X-ray/Computed Tomography, Magnetic Resonance Imaging and Ultrasound), By Indication, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年全球對比媒體市場價值為 48.6 億美元，預計到 2029 年將以 4.29% 的複合CAGR成長。全球對比媒體市場是由全球人口老齡化和慢性病患病率日益上升推動的。這反過來又顯著增加了對先進診斷成像程序的需求，從而推動了對造影劑的需求。 X光、CT掃描、MRI和超音波等醫學影像技術的進步有助於擴大造影劑的應用，並提高診斷的準確性和效率。造影劑不僅用於傳統影像技術，也應用於介入放射學程序和影像引導治療。造影劑應用範圍的擴大進一步促進了全球造影劑市場的成長。

朝向個人化醫療的典範轉移需要精確的診斷工具來客製化治療方法。能夠為個別患者提供特定分子標靶或影像特徵的造影劑配方將有助於未來幾年需求的成長，從而為全球造影劑市場的成長創造有利可圖的機會。根據患者個別特徵和醫療狀況定製造影劑可提高診斷精度並最大限度地減少不良反應。這與更廣泛的精準醫學運動一致，即根據患者獨特的遺傳、環境和生活方式因素來客製化治療方法。

主要市場促進因素

增加診斷成像程序

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球對比媒體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 依類型（碘造影劑、钆造影劑、微泡造影劑和鋇造影劑）
    • 按程序（X 光/電腦斷層掃描 (CT)、磁振造影 (MRI) 和超音波）
    • 按適應症（心血管疾病、腫瘤、胃腸道疾病、神經系統疾病和其他適應症）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美對比媒體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型
    • 按程式
    • 按指示
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲對比媒體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型
    • 按程式
    • 按指示
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區對比媒體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型
    • 按程式
    • 按指示
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲對比媒體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型
    • 按程式
    • 按指示
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲對比媒體市場展望

  • 市場規模預測
    • 按價值
  • 市佔率預測
    • 按類型
    • 按程式
    • 按指示
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢發展

  • 近期發展
  • 併購
  • 產品發布

第 13 章：全球對比媒體市場：SWOT 分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第15章：競爭格局

  • Bayer AG
  • Bracco Diagnostic Inc. (Bracco Group)
  • GE Healthcare Technologies Inc.
  • Guerbet Group
  • Lantheus Medical Imaging Inc
  • Spago Nanomedical AB
  • FUJIFILM Holdings Corporation
  • Beijing Beilu Pharmaceutical Company Limited
  • TAEJOON Pharmaceutical Co.,Ltd.

第 16 章：策略建議

第 17 章：關於我們免責聲明

簡介目錄
Product Code: 23531

Global Contrast Media Market was valued at USD 4.86 Billion in 2023 and is anticipated to grow with a CAGR of 4.29% through 2029.The Global Contrast MediaMarket is driven by an aging global population and an increasing prevalence of chronic diseases. This in turn has significantly increased the demand for advanced diagnostic imaging procedures, fueling the need for contrast media. The technological advancements in medical imaging, such as X-ray, CT scans, MRI, and ultrasound, contribute to the expanding applications of contrast agents, enhancing the accuracy and efficiency of diagnoses. Contrast Media are not only used in traditional imaging techniques but also find applications in interventional radiology procedures and image-guided therapies. The expanding scope of applications of contrast media further contributes to the growth of global contrast media market.

The paradigm shift towards personalized medicine necessitates precise diagnostic tools for tailored treatment approaches. Contrast media formulations that can provide specific molecular targeting or imaging characteristics to individual patients would contribute to an increasing demand in the coming years, thereby creating lucrative opportunities for the growth of global contrast media market. Tailoring contrast agents to individual patient characteristics and medical conditions enhances diagnostic precision and minimizes adverse reactions. This aligns with the broader movement towards precision medicine, where treatments are customized based on patients unique genetic, environmental and lifestyle factors.

Key Market Drivers

Increasing Diagnostic Imaging Procedures

In the dynamic landscape of medical diagnostics, technological innovations play a pivotal role in shaping the trajectory of the contrast media market. As the industry witnesses a relentless pursuit of cutting-edge advancements, the seamless integration of these technologies into diagnostic imaging procedures has become a key driver for market growth.

In recent years, the surge in diagnostic imaging procedures, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and angiography, has been a conspicuous trend. This surge can be attributed to the increasing need for accurate and timely diagnoses of various medical conditions. Notably, these imaging techniques rely heavily on the use of contrast media to enhance the visibility of internal structures, making them indispensable tools for healthcare professionals.

The escalating prevalence of chronic diseases, such as cardiovascular ailments and cancer, further amplifies the demand for diagnostic imaging procedures. Contrast media, with its ability to provide clearer and more detailed images, becomes instrumental in facilitating early detection and precise monitoring of these diseases. The aging global population, prone to age-related illnesses, contributes significantly to the sustained growth of the contrast media market.

Simultaneously, the realm of imaging technologies is undergoing rapid evolution, fueled by relentless innovation. High-resolution imaging and three-dimensional (3D) imaging technologies are becoming increasingly prevalent, driving the quest for more sophisticated and effective contrast agents. These advancements not only improve diagnostic accuracy but also open new avenues for personalized and targeted medical interventions.

The rise in healthcare expenditure globally is a catalyst for the adoption of advanced medical imaging technologies and contrast media. As healthcare systems prioritize investments in state-of-the-art diagnostic equipment, the demand for contrast media is propelled forward. Governments and private institutions alike are recognizing the pivotal role of contrast media in achieving diagnostic excellence, thereby allocating resources to enhance the accessibility and affordability of these technologies.

Stringent regulatory standards and compliance measures have become synonymous with the global contrast media market. Regulatory bodies play a crucial role in ensuring the safety and efficacy of contrast agents, thereby fostering trust among healthcare providers and patients. The adherence to these standards not only safeguards patient well-being but also contributes to the overall sustainability and credibility of the global contrast media market.

Increasing Chronic Disease Prevalence

The prevalence of chronic diseases represents a significant and escalating health challenge globally. Chronic diseases, characterized by prolonged and often slow-progressing conditions, encompass a diverse range of illnesses, including cardiovascular diseases, diabetes, cancer, and respiratory disorders. Several factors contribute to the increasing prevalence of these conditions, including aging populations, unhealthy lifestyle choices, and changes in dietary habits. As life expectancy rises, the likelihood of individuals developing chronic diseases also increases, placing a considerable burden on healthcare systems. The impact extends beyond individual health, affecting societal well-being and healthcare resources. The rising prevalence of chronic diseases require the need for early diagnosis and treatment. Chronic diseases such as neurological disorders, cardiovascular diseases, cancer, among others are effectively diagnosed using different kinds of imaging procedures. Contrast media plays a significant role in the accurate diagnosis and monitoring of these diseases, thereby fueling the global contrast media market growth.

Technological Advancements in Imaging Modalities

Technological advancements in medical imaging modalities represent a significant driver for the growth of the Global Contrast Media Market. Continuous innovations in X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound technologies have transformed diagnostic imaging, making it more precise and efficient. These advancements not only enable healthcare professionals to visualize internal structures with higher clarity but also expand the applications of contrast media.

For example, the development of high-resolution CT scanners and advanced MRI techniques allows for detailed imaging of soft tissues and vascular structures. Contrast media enhance the visibility of specific anatomical or pathological features during these procedures, providing crucial information for accurate diagnoses. Improved imaging technologies contribute to early detection, better characterization of diseases, and more targeted treatment strategies.

Companies in the contrast media market invest in research and development to align their products with the latest imaging technologies. The synergy between contrast agents and cutting-edge imaging modalities enhances diagnostic accuracy, driving the adoption of contrast-enhanced imaging across various medical specialties. As technological innovations continue, this driver remains integral to the market's growth, ensuring that contrast media play a pivotal role in the advancement of diagnostic capabilities in healthcare.

Patient Preferences for Non-Invasive Procedures

In recent years, a discernible shift in patient preferences has been observed within the realm of diagnostic imaging, with a notable inclination towards non-invasive procedures. This evolving trend has substantially influenced the dynamics of the contrast media market, as patients increasingly prioritize diagnostic methods that eschew invasive surgeries while maintaining high diagnostic accuracy. This transformation is rooted in the desire for a more patient-friendly and comfortable diagnostic experience.

As technology in the medical field advances, non-invasive diagnostic procedures have gained prominence, leveraging techniques such as CT scans, MRI scans, and angiography. These procedures, which often necessitate the use of contrast media, enable healthcare professionals to obtain detailed and precise images without resorting to intrusive interventions. The appeal of non-invasiveness lies not only in its ability to reduce patient discomfort but also in its potential to minimize recovery times and associated healthcare costs.

Furthermore, the preference for non-invasive procedures aligns with broader societal trends, where patients are becoming increasingly proactive in managing their health. The accessibility of information has empowered individuals to make informed choices about their medical care. Consequently, patients are more likely to opt for diagnostic methods that offer a balance between diagnostic efficacy and a minimally intrusive experience. The prominence of patient-centric care in the healthcare landscape has intensified the demand for imaging technologies that prioritize comfort and convenience.

The rise in patient preferences for non-invasive procedures has profound implications for companies operating in the contrast media market. Manufacturers of contrast agents must respond to this paradigm shift by developing products that not only enhance imaging capabilities but also prioritize safety, comfort, and ease of administration. Investing in research and development to create contrast agents with improved properties, such as reduced side effects and shorter administration times, becomes imperative to meet the evolving expectations of both healthcare professionals and patients.

Healthcare providers, too, need to adapt their service offerings to align with patient preferences. Investing in state-of-the-art imaging equipment and incorporating the latest contrast media technologies can enhance diagnostic capabilities while simultaneously catering to the growing demand for non-invasive procedures. Marketing strategies should be tailored to communicate the benefits of these advanced diagnostic methods, emphasizing the patient-friendly aspects that resonate with the evolving expectations of the healthcare consumer.

Key Market Challenges

Competition from Alternative Imaging Technologies

Alternative imaging techniques, such as PET scans and optical imaging modalities, pose competition to traditional contrast-enhanced imaging modalities like CT and MRI. The development of novel imaging techniques may disrupt the demand for contrast media. PET scans offer functional imaging capabilities that provide insights into metabolic activity and physiological processes. Compared to traditional anatomical imaging modalities like CT and MRI, PET scans can offer greater sensitivity and specificity in detecting certain diseases, such as cancer. The development of novel PET tracers continues to expand the clinical applications of PET imaging, potentially reducing the demand for contrast-enhanced CT or MRI scans in specific diagnostic scenarios. Similarly, optical imaging techniques, including fluorescence imaging and photoacoustic imaging, offer high resolution and real-time visualization of biological tissues. These modalities are particularly valuable in intraoperative imaging and preclinical research settings.

Safety Concerns

Adverse reactions to contrast media, such as allergic reactions, nephrotoxicity (especially with iodinated contrast media), and gadolinium retention (with certain MRI contrast agents), raise safety concerns among patients and healthcare providers.Allergic reactions are more common in patients with a history of allergies, asthma, or previous reactions to contrast agents. Managing allergic risks involves pre-screening patients, administering premedication when appropriate, and having emergency protocols in place to address acute reactions. Addressing these safety issues is essential to maintain trust in contrast media products. Iodinated contrast media, commonly used in CT scans, pose a risk of contrast-induced nephropathy (CIN), especially in patients with pre-existing kidney dysfunction. Strategies to mitigate nephrotoxicity include hydration protocols, selecting low-osmolality contrast agents, and avoiding unnecessary contrast administration in high-risk patients.

Key Market Trends

Shift towards Non-Ionic Contrast Agents

Ionic contrast agents contain positively or negatively charged particles, which can contribute to adverse reactions such as nephrotoxicity and allergic responses. Non-ionic contrast agents, on the other hand, have a reduced risk of adverse reactions due to their lower osmolality and reduced ion content. Non-ionic contrast agents are associated with a lower incidence of adverse reactions compared to ionic formulations. These reactions can range from mild symptoms such as nausea and rash to severe complications like anaphylaxis. Healthcare providers increasingly prefer non-ionic agents, particularly for high-risk patients and procedures, to minimize the risk of adverse events. Non-ionic contrast agents are often better tolerated by patients due to their reduced osmolality, which mitigates the discomfort associated with contrast administration. This improved patient comfort contributes to better overall patient experience during diagnostic procedures, leading to higher patient satisfaction rates.

Emergence of Theranostic Contrast Agents

Theranostic agents represent a convergence of diagnostic imaging and therapeutic capabilities within a single contrast agent. These agents enable not only the visualization of anatomical structures but also the monitoring of therapeutic responses and targeted drug delivery. Theranostic agents facilitate a personalized medicine approach by combining diagnostic imaging with therapeutic interventions. By incorporating both diagnostic and therapeutic functionalities into a single agent, theranostic contrast media enable clinicians to tailor treatment strategies based on individual patient characteristics and disease profiles.

Segmental Insights

Procedure Insights

By Procedure, X-ray/CT segment dominated in the Global Contrast Media Market in 2023 owing to numerous factors. X-ray and CT scans are widely used in diagnostic imaging techniques across medical settings. These imaging modalities play a crucial role in identifying and diagnosing a variety of medical conditions, ranging from bone fractures to internal organ abnormalities. Contrast media are substances injected into the body to enhance the visibility of specific tissues or organs during imaging procedures. In the case of X-ray and CT scans, contrast media help highlight blood vessels, organs, or other structures, providing greater clarity and detail in the resulting images. The increased diagnostic accuracy achieved using contrast agents in X-ray and CT scans has likely contributed to the segment's dominance. Furthermore, advancements in technology and imaging equipment have improved the overall performance and safety of contrast media used in X-ray and CT procedures.

Regional Insights

In 2023, the Contrast Media Market witnessed North America emerging as the unrivaled leader, solidifying its position through a confluence of factors that delineate its dominance.Several key elements contribute to the region's preeminence in this dynamic market landscape. Foremost among these factors is the robust infrastructure and technological prowess embedded within North America's healthcare system. The region boasts cutting-edge medical facilities and a comprehensive network of diagnostic imaging centers, which are pivotal in the administration of contrast media for various diagnostic procedures. The seamless integration of advanced imaging technologies, such as magnetic resonance imaging (MRI) and computed tomography (CT), across healthcare institutions in North America positions it at the forefront of diagnostic capabilities, consequently driving the demand for contrast media.

Additionally, the proactive approach of North America healthcare providers towards the adoption of novel medical technologies and contrast agents has significantly propelled market growth. The region exhibits a remarkable willingness to invest in research and development activities, resulting in the continual evolution of contrast media formulations with improved safety profiles and enhanced imaging capabilities. This commitment to innovation positions North America as a trendsetter, influencing global standards in the development and application of contrast media within diagnostic imaging.

Key Market Players

Bayer AG

Bracco Diagnostic Inc. (Bracco Group)

GE Healthcare Technologies Inc.

Guerbet Group

Lantheus Medical Imaging Inc

Spago Nanomedical AB

FUJIFILM Holdings Corporation

Beijing Beilu Pharmaceutical Company Limited

TAEJOON Pharmaceutical Co., Ltd.

Report Scope:

In this report, the Global Contrast Media Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Contrast Media Market,By Type:

Iodinated Contrast Media

Gadolinium-based Contrast Media

Microbubble Contrast Media

Barium-based Contrast Media

Contrast Media Market,By Procedure:

X-ray/Computed Tomography (CT)

Magnetic Resonance Imaging (MRI)

Ultrasound

Contrast Media Market,By Indication:

Cardiovascular Disease

Oncology

Gastrointestinal Disorders

Neurological Disorders

Other Indications

Contrast Media Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • United Kingdom
  • Italy
  • France
  • Spain

Asia Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia

South America

  • Brazil
  • Argentina
  • Colombia

Middle East Africa

  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Contrast Media Market.

Available Customizations:

Global Contrast Media Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validations
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, Trends

4.Voice of Customer

5.GlobalContrast Media MarketOutlook

  • 5.1.Market Size Forecast
    • 5.1.1.By Value
  • 5.2.Market Share Forecast
    • 5.2.1.By Type (Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, and Barium-based Contrast Media)
    • 5.2.2.By Procedure (X-ray/Computed Tomography (CT), Magnetic Resonance Imaging (MRI) and Ultrasound)
    • 5.2.3.By Indication (Cardiovascular Disease, Oncology, Gastrointestinal Disorders, Neurological Disorders, and Other Indications)
    • 5.2.4.By Region
    • 5.2.5.By Company (2023)
  • 5.3.Market Map

6.North America Contrast Media Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Type
    • 6.2.2.By Procedure
    • 6.2.3.By Indication
    • 6.2.4.By Country
  • 6.3.North America: Country Analysis
    • 6.3.1.United States Contrast Media Market Outlook
      • 6.3.1.1.Market Size Forecast
        • 6.3.1.1.1.By Value
      • 6.3.1.2.Market Share Forecast
        • 6.3.1.2.1.By Type
        • 6.3.1.2.2.By Procedure
        • 6.3.1.2.3.By Indication
    • 6.3.2.Canada Contrast Media Market Outlook
      • 6.3.2.1.Market Size Forecast
        • 6.3.2.1.1.By Value
      • 6.3.2.2.Market Share Forecast
        • 6.3.2.2.1.By Type
        • 6.3.2.2.2.By Procedure
        • 6.3.2.2.3.By Indication
    • 6.3.3.Mexico Contrast Media Market Outlook
      • 6.3.3.1.Market Size Forecast
        • 6.3.3.1.1.By Value
      • 6.3.3.2.Market Share Forecast
        • 6.3.3.2.1.By Type
        • 6.3.3.2.2.By Procedure
        • 6.3.3.2.3.By Indication

7.Europe Contrast Media Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Type
    • 7.2.2.By Procedure
    • 7.2.3.By Indication
    • 7.2.4.By Country
  • 7.3.Europe: Country Analysis
    • 7.3.1.Germany Contrast Media Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Type
        • 7.3.1.2.2.By Procedure
        • 7.3.1.2.3.By Indication
    • 7.3.2.United Kingdom Contrast Media Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Type
        • 7.3.2.2.2.By Procedure
        • 7.3.2.2.3.By Indication
    • 7.3.3.Italy Contrast Media Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecasty
        • 7.3.3.2.1.By Type
        • 7.3.3.2.2.By Procedure
        • 7.3.3.2.3.By Indication
    • 7.3.4.France Contrast Media Market Outlook
      • 7.3.4.1.Market Size Forecast
        • 7.3.4.1.1.By Value
      • 7.3.4.2.Market Share Forecast
        • 7.3.4.2.1.By Type
        • 7.3.4.2.2.By Procedure
        • 7.3.4.2.3.By Indication
    • 7.3.5.Spain Contrast Media Market Outlook
      • 7.3.5.1.Market Size Forecast
        • 7.3.5.1.1.By Value
      • 7.3.5.2.Market Share Forecast
        • 7.3.5.2.1.By Type
        • 7.3.5.2.2.By Procedure
        • 7.3.5.2.3.By Indication

8.Asia-Pacific Contrast Media Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Type
    • 8.2.2.By Procedure
    • 8.2.3.By Indication
    • 8.2.4.By Country
  • 8.3.Asia-Pacific: Country Analysis
    • 8.3.1.China Contrast Media Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Type
        • 8.3.1.2.2.By Procedure
        • 8.3.1.2.3.By Indication
    • 8.3.2.India Contrast Media Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Type
        • 8.3.2.2.2.By Procedure
        • 8.3.2.2.3.By Indication
    • 8.3.3.Japan Contrast Media Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Type
        • 8.3.3.2.2.By Procedure
        • 8.3.3.2.3.By Indication
    • 8.3.4.South Korea Contrast Media Market Outlook
      • 8.3.4.1.Market Size Forecast
        • 8.3.4.1.1.By Value
      • 8.3.4.2.Market Share Forecast
        • 8.3.4.2.1.By Type
        • 8.3.4.2.2.By Procedure
        • 8.3.4.2.3.By Indication
    • 8.3.5.Australia Contrast Media Market Outlook
      • 8.3.5.1.Market Size Forecast
        • 8.3.5.1.1.By Value
      • 8.3.5.2.Market Share Forecast
        • 8.3.5.2.1.By Type
        • 8.3.5.2.2.By Procedure
        • 8.3.5.2.3.By Indication

9.South America Contrast Media Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Type
    • 9.2.2.By Procedure
    • 9.2.3.By Indication
    • 9.2.4.By Country
  • 9.3.South America: Country Analysis
    • 9.3.1.Brazil Contrast Media Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Type
        • 9.3.1.2.2.By Procedure
        • 9.3.1.2.3.By Indication
    • 9.3.2.Argentina Contrast Media Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Type
        • 9.3.2.2.2.By Procedure
        • 9.3.2.2.3.By Indication
    • 9.3.3.Colombia Contrast Media Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Type
        • 9.3.3.2.2.By Procedure
        • 9.3.3.2.3.By Indication

10.Middle East and Africa Contrast Media Market Outlook

  • 10.1.Market Size Forecast
    • 10.1.1.By Value
  • 10.2.Market Share Forecast
    • 10.2.1.By Type
    • 10.2.2.By Procedure
    • 10.2.3.By Indication
    • 10.2.4.By Country
  • 10.3.MEA: Country Analysis
    • 10.3.1.South Africa Contrast Media Market Outlook
      • 10.3.1.1.Market Size Forecast
        • 10.3.1.1.1.By Value
      • 10.3.1.2.Market Share Forecast
        • 10.3.1.2.1.By Type
        • 10.3.1.2.2.By Procedure
        • 10.3.1.2.3.By Indication
    • 10.3.2.Saudi Arabia Contrast Media Market Outlook
      • 10.3.2.1.Market Size Forecast
        • 10.3.2.1.1.By Value
      • 10.3.2.2.Market Share Forecast
        • 10.3.2.2.1.By Type
        • 10.3.2.2.2.By Procedure
        • 10.3.2.2.3.By Indication
    • 10.3.3.UAE Contrast Media Market Outlook
      • 10.3.3.1.Market Size Forecast
        • 10.3.3.1.1.By Value
      • 10.3.3.2.Market Share Forecast
        • 10.3.3.2.1.By Type
        • 10.3.3.2.2.By Procedure
        • 10.3.3.2.3.By Indication

11.Market Dynamics

  • 11.1.Drivers
  • 11.2.Challenges

12.Market Trends Developments

  • 12.1.Recent Development
  • 12.2.Mergers Acquisitions
  • 12.3. Product Launches

13.Global Contrast Media Market: SWOT Analysis

14.Porter's Five Forces Analysis

  • 14.1.Competition in the Industry
  • 14.2.Potential of New Entrants
  • 14.3.Power of Suppliers
  • 14.4.Power of Customers
  • 14.5.Threat of Substitute Products

15.Competitive Landscape

  • 15.1.Bayer AG
    • 15.1.1.Business Overview
    • 15.1.2.Product Service Offerings
    • 15.1.3.Recent Developments
    • 15.1.4.Key Personnel
    • 15.1.5.SWOT Analysis
  • 15.2.Bracco Diagnostic Inc. (Bracco Group)
  • 15.3.GE Healthcare Technologies Inc.
  • 15.4.Guerbet Group
  • 15.5.Lantheus Medical Imaging Inc
  • 15.6.Spago Nanomedical AB
  • 15.7.FUJIFILM Holdings Corporation
  • 15.8.Beijing Beilu Pharmaceutical Company Limited
  • 15.9.TAEJOON Pharmaceutical Co.,Ltd.

16.Strategic Recommendations

17.About Us Disclaimer